Key indicators: single-crystal X-ray study; T = 293 K; mean (C-C) = 0.007 Å; R factor = 0.053; wR factor = 0.139; data-to-parameter ratio = 15.5.
Related literature
For biological applications of Schiff base compounds, see: Liang (2003) ; Bacci et al. (2005) . For the biological activity of triazoles and their derivatives, see: Amir et al. (2008) ; Sztanke et al. (2008) ; Padmavathi et al. (2008) ; Thenmozhi et al. (2010) . Pharmacological compounds having triazole moieties appear to be very effective aromatese inhibitors for the prevention of breast cancer, see: Ü nver et al. (2010) .
Experimental
Crystal data C 19 H 20 N 6 S 2 M r = 396.53
Monoclinic, Cc a = 13.384 (3) Å b = 13.892 (3) Å c = 11.349 (2) Å = 101.953 (3) V = 2064.5 (7) Å 3 Z = 4 Mo K radiation = 0.27 mm À1 T = 293 K 0.28 Â 0.25 Â 0.23 mm
Data collection
Bruker SMART APEX CCD areadetector diffractometer 7754 measured reflections 3788 independent reflections 3391 reflections with I > 2(I) R int = 0.017 Refinement R[F 2 > 2(F 2 )] = 0.053 wR(F 2 ) = 0.139 S = 1.07 3788 reflections 244 parameters 2 restraints H-atom parameters constrained Á max = 0.33 e Å À3 Á min = À0.21 e Å À3 Table 1 Hydrogen-bond geometry (Å , ) .
Symmetry code: (i) x À 1 2 ; Ày þ 1 2 ; z þ 1 2 .
Data collection: APEX2 (Bruker, 2004) ; cell refinement: SAINT (Bruker, 2004) ; data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: ORTEP-3 (Farrugia, 1997); software used to prepare material for publication: PLATON (Spek, 2009) .
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: KJ2187).
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Comment Synthesis and structural investigation of Schiff base compounds have been given attention due to their interesting structural features and potential biological applications (Liang, 2003; Bacci et al., 2005) . The biological importance of imidazoles and triazoles has stimulated much work on these heterocycles. Triazole compounds and their derivatives have many applications in medicine and were reported to exhibit various pharmacological activities such as antimicrobial, analgesic, anti-inflammatory, anticancer and antioxidant properties (Amir et al., 2008; Sztanke et al., 2008; Padmavathi et al., 2008; Thenmozhi et al., 2010) . The 1,2,4-triazole group interacts strongly with heme iron and aromatic substituents on the triazoles are very effective for interacting with the active site of aromatase. Furthermore, it was reported that pharmacological compounds having triazole moieties such as Vorozole, Anastrozole and Letrozole appear to be very effective aromatese inhibitors for preventing breast cancer (Ünver et al., 2010) . In view of these important applications of imidazolines, here we report the crystal structure of the title compound (Fig. 1) .
The title compound contains imidazole and 1,2,4-triazole rings connected by an imine group. A phenyl ring is substituted at position 5 of the triazole ring and the dihedral angle between these rings is 24.1 (2)°. The imidazole and triazole groups are substituted on the imine group (N12-C13) in the E-configuration [N1-N12-C13-C14 = -174.4 (3)°]. The triazole ring is not co-planar with the imidazole ring and this may be due to the substitution of the phenyl ring on the triazole ring. The dihedral angles between the imidazole ring and the triazole and phenyl rings are 39.9 (2)° and 55.3 (2)°, respectively. The imidazole ring is substituted by bulky groups (3-butene, 2-propene) as well as an imine and a thiol group, which gives strain on the ring. The 3-butene and imine substituents show an extended zigzag confirmation with respect to the imidazole ring.
The packing diagram of the title compound viewed down the a axis is shown in Fig. 2 . The crystal packing displays intermolecular N-H···N hydrogen bonds (Table 1) , which join the molecules into chains in the [1 0 -1] direction.
Experimental
The title compound was synthesized by refluxing 4-amino-5-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione (0.01 mmol) and 2-(but-3-en-1-yl)-1-(prop-2-en-1-yl)-4-sulfanyl-1H-imidazole-5-carbaldehyde (0.01 mmol) in ethanol (50 ml) with a few drops of H 2 SO 4 for 3 h on a water bath. The reaction progress was monitored by TLC. The resulting precipitate was filtered off, washed with cold ethanol, dried and purified to give the target product as a colorless solid in 74% yield. The resulting Schiff base compound was seperated out and crystallized in ethanol.
Refinement
H atoms were positioned geometrically, taking H-bond formation potential into account where necessary, and refined using a riding model with C-H = 0.93 Å for aromatic H, 0.97 Å for methylene, for aromatic N-H = 0.86 Å and for S-H = Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating Rfactors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq S1 0.62454 (8) Geometric parameters (Å, °) S1-C15 1.711 (4) C14-C15 1.365 (4) S1-H1 
